Taysha Gene Therapies, Inc. (TSHA)
NASDAQ: TSHA · Real-Time Price · USD
6.37
-0.19 (-2.90%)
At close: Aug 10, 2026, 4:00 PM EDT
6.37
0.00 (0.00%)
After-hours: Aug 10, 2026, 4:08 PM EDT
Taysha Gene Therapies Employees
Taysha Gene Therapies had 99 employees as of December 31, 2025. The number of employees increased by 26 or 35.62% compared to the previous year.
Employees
99
Change (1Y)
26
Growth (1Y)
35.62%
Revenue / Employee
$75,465
Profits / Employee
-$1,311,879
Market Cap
2.04B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 99 | 26 | 35.62% |
| Dec 31, 2024 | 73 | 21 | 40.38% |
| Dec 31, 2023 | 52 | -13 | -20.00% |
| Dec 31, 2022 | 65 | -113 | -63.48% |
| Dec 31, 2021 | 178 | 140 | 368.42% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| ADMA Biologics | 647 |
| AbCellera Biologics | 562 |
| Ocular Therapeutix | 325 |
| Harmony Biosciences Holdings | 293 |
| Biohaven | 274 |
| Stoke Therapeutics | 170 |
| Zenas BioPharma | 167 |
| Aurinia Pharmaceuticals | 128 |
TSHA News
- 3 days ago - Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 days ago - Taysha Gene Therapies to Release Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 11 - GlobeNewsWire
- 7 days ago - Taysha Gene Therapies, Catalent announce commercial supply pact for TSHA-102 - TheFly
- 7 days ago - Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome - GlobeNewsWire
- 20 days ago - Taysha Gene Therapies price target raised to $13 from $11 at Goldman Sachs - TheFly
- 4 weeks ago - Taysha Gene Therapies falls -11.0% - TheFly
- 5 weeks ago - Taysha Gene Therapies Slides: Corporate presentation - Filings
- 5 weeks ago - Taysha Gene Therapies price target raised to $15 from $12 at Baird - TheFly